Skip to main content
Erschienen in: BMC Infectious Diseases 1/2019

Open Access 01.12.2019 | Research article

Association of TGF-ß1 polymorphisms and chronic hepatitis C infection: a Meta-analysis

verfasst von: Pengfei Guo, Shuangyin Liu, Xiangru Sun, Longqin Xu

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2019

Abstract

Background

Although several researches have reported the connection between the transforming growth factor-beta 1 (TGF-β1) gene polymorphisms and chronic hepatitis C virus (HCV) infection, the conclusions of these studies were not always consistent. Here, this paper proposed a meta-analysis to evaluate whether the TGF-ß1 gene polymorphisms, −509C/T (rs1800469), codon 10 T/C (rs1982073) and codon 25G/C (rs1800471), were associated with chronic HCV infection.

Methods

The summary odds ratios (ORs) of chronic HCV infected patients and controls with all SNPs were obtained by adaptive fixed or random effect model. A series of statistical tools were employed to guarantee the accuracy of related pooling ORs, including the Hardy-Weinberg equilibrium (HWE) test, sensitivity analysis and publication bias test.

Results

This paper analyzed 18 case-control studies in 17 articles which totally contains 2718 chronic HCV infection cases corresponding to 1964 controls. The results of the meta-analysis indicated that the −509C/T polymorphism effected an increased risk of chronic HCV infection in all gene models. More specifically by ethnicity stratification, the Egyptians shared the similar association with the above overall study. Moreover, the meta-fusion of healthy control studies showed that − 509 T allele carriers (TT + TA) had nearly 2.00 and 3.36 fold higher risk of chronic HCV infection in the total and Egyptian populations, respectively (OR = 2.004, 95% CI = 1.138–3.528, P = 0.016; OR = 3.363, 95% CI = 1.477–7.655, P = 0.004, respectively). However, our meta-analysis did not find any significant association between the codon 10 T/C or codon 25G/C polymorphisms and chronic HCV infection.

Conclusions

Our results suggested that the TGF-ß1–509C/T polymorphism may effect an increased risk of chronic HCV infection, especially in Egyptian population.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12879-019-4390-8) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AS
Asymptomatic carriers
CHC
Chronic hepatitis C
CI
Confidence interval
HCC
Hepatocellular carcinoma
HCV/HBV
Hepatitis C/B virus
HIV
Human immunodeficiency virus
HWE
Hardy–Weinberg equilibrium
IFN-γ
Interferon-gamma
IL
Interleukin
LC
Liver cirrhosis
NK
Natural killer
OR
Odds ratio
SNPs
Single-nucleotide polymorphisms
SR
Spontaneously recovered
TGF-ß
Transforming growth factor-beta

Background

Hepatitis C virus (HCV) infection which is a widely prevalent infectious disease has presented in about 170 million people of the world [1]. There are 60–80% of patients with the acute infection developing into chronic hepatitis C (CHC). In the long run, one out of three CHC patients will progress to hepatic complications such as hepatic fibrosis, liver cirrhosis (LC), eventually hepatocellular carcinoma (HCC), which leads to high mortality [2]. For a long time, scientists have revealed the factors which regulate the responses to HCV infection and affect disease progression. Some studies reported that the viral genotypes, environmental factors and behavioral factors (excessive alcohol intake) were implicated in the development of HCV infection [3, 4]. However, these factors cannot fully explain the large variability in susceptibility or outcomes observed within different populations. Recently, several genetic association studies concluded that the mutations of certain cytokine genes may play an important role in the susceptibility and progression of HCV infection, due to the insufficient or imbalance responses in the cytokine network [57].
Transforming growth factor-beta 1 (TGF-β1), which is an crucial immuno-regulatory cytokine secreted by hepatic stellate cells, fibroblasts, and Kupffer cells, is participated in the regulation of cellular growth, differentiation and proliferation [8]. During the acute infectious stage of HCV, natural killer (NK) cells produce interferon-gamma (IFN-γ), and the proliferation and cytotoxicity of NK cells are pivotal in clearing HCV infection. As a renowned suppressor of NK cells, TGF-β1 inhibits the secretion of IFN-γ and interleukin (IL) -12, leading to the persistence of HCV infection [6]. In different infection states, the frequent mutations and expression of TGF-β1 were various implying a possible role of TGF-β1 in HCV infection [6, 9]. The TGF-β1 gene which is located in chromosome 19q13.1 is constituted by 7 exons and 6 introns. To date, several functional single-nucleotide polymorphisms (SNPs) of TGF-β1 have been reported. Particularly, the −509C/T (rs1800469), codon 25G/C (rs1800471), and codon 10 T/C (rs1982073) SNPs are the most widely evaluated polymorphisms [10, 11]. It has been demonstrated that these functional SNPs are associated with the interindividual differences of TGF-β1 expression [6, 7]. The above facts suggest that −509C/T, codon 25G/C, and codon 10 T/C SNPs may contribute to TGF-β1-mediated immune response in HCV infection.
Recently, great attention has paid to investigate whether the −509C/T, codon 25G/C, and codon 10 T/C SNPs of TGF-β1 gene were associated with the chronic HCV infection. Pooling the related research’s data, we found that the conclusions of these studies were not always consistent. Taking the TGF-β1–509C/T polymorphism as an example, most studies suggested that people with the −509TT genotype and T allele have a higher risk of chronic HCV infection [6, 7, 12, 13]; and Kimura et al. described −509CC genotype and C allele may contribute to HCV clearance rates in Japanese populations [14]; however, no association has been shown in another study [15]. These reported discrepancies may result from the differences of individual studies in sample size, as well as geographical region and ethnicity of the subjects.
In this paper, we proposed a meta-analysis by pooling the small size case-control results statistically to further clarify the role of TGF-ß1–509C/T (rs1800469), codon 10 T/C (rs1982073), and codon 25G/C (rs1800471) polymorphisms in chronic HCV infection in order to overcome the drawbacks of unbalance sampling data-driven experiment result.

Methods

Identification of eligible studies

The genetic association studies which was adopted by this paper published before May 2019. The adopted articles of TGF-ß1 gene polymorphisms and HCV infection were sought in PubMed, Web of Science and EMBASE (Excerpta Medica Data base). The keywords of search were used as follow: (Transforming Growth Factor-beta OR TGF-ß1) AND (Polymorphism OR SNP) AND (HCV infection OR clearance), without language restriction. Additionally, we searched the other related review articles and the references of articles by hand identifying.

Inclusion and exclusion criteria

Defining an article as eligible study if: (i) The article conducted an evaluation of the association of TGF-ß1 gene polymorphisms (−509C/T, codon 25G/C and codon 10 T/C) with the spontaneous clearance of HCV or the susceptibility of chronic HCV infection; (ii) The article was a case-control or cohort study; (iii) The article provided enough subjects data to calculate the odds ratios (ORs) of association with 95% confidence intervals (CIs). One study will be excluded if the patients were reported as co-infected (infected) with the other virus (human immune deficiency virus, HIV or HBV) or the liver transplant recipients. For the overlapping studies, we selected the most recent or complete publication.

Definitions

The definition of asymptomatic carriers (AS) of HCV is as follow: (i) The patients have been infected persistently with HCV; (ii) The patients don’t display sign/symptom; (iii) There exists necro-inflammatory cells.
CHC can be described as follow: (i) CHC is a chronic neuroinflammatory disease of the liver; (ii) The index of anti-HCV antibodies is positive; (iii) The index of HCV RNA is positive. Usually, CHC is caused by the persistent infection with HCV.
The spontaneously recovered (SR) subjects of HCV infection can be defined by the following conditions: (i) The index of anti-HCV antibodies is positive; (ii) The index of HCV RNA is negative; (iii) The function tests of liver are normal; (iv). No history of HCV vaccination. In this paper, we discussed the problem of chronic HCV infection which consisted of CHC, AS and liver cirrhosis.

Data extraction

Information was extracted from these included studies by two of the authors independently (Guo PF and Sun XR). We extracted the following detail information from the included studies: the name of the first author, the year of publication, the ethnicity, the geographic location, genotyping method, definitions and total amount of cases and controls, frequency of genotypes. The control groups were further divided into the SR and healthy control groups.

Quality assessment

In order to make our results more credible, we conducted a quality assessment of the included studies according to the scale of the properties of the piece study data (details showed in Additional file 4: Table S4). Five items were assessed in this scale, including the representation of the cases, the source of controls, the number of samples, the genotyping method’s quality control and the Hardy-Weinberg equilibrium (HWE). The quality of studies was scored by integrals which was ranged in interval (0–10). The lower scored studies have been dropped by careful discussion. The results of quality assessment were shown in Table 1.
Table 1
Characteristics of studies evaluating the effects of TGF-ß1 gene polymorphisms on chronic HCV infection of the Meta-Analysis
First author
Year
Country
Ethnicity
QA
Genotyping
Case
Control
Position
[Reference]
method
Sample
Numbers
Sample
Numbers
Larijani [16]
2016
Iran
Caucasian
7
PCR-AS
CHC
89
Healthy
76
-509
Ma [13]
2015
China
Asian
6
PCR-RFLP
CHC
393
Healthy
375
-509
Imran [17]
2014
Pakistan
Asian
7
PCR-AS
CHC
140
Healthy
120
codon 10,25
Mohy [6]
2014
Egypt
Egyptian
4
PCR-RFLP
LC
40
Healthy
40
-509
Rebbani [18]
2014
Morocco
Mix
8
PCR-RFLP
CHC
119
Healthy
137
codon 25
        
SR
54
codon 25
Pasha [14]
2013
Egypt
Egyptian
9
PCR-SSP
CHC
440
Healthy
220
-509
Radwan [7]
2012
Egypt
Egyptian
9
PCR-RFLP
CHC
280
Healthy
160
-509
Romani [15]
2011
Iran
Caucasian
9
PCR-RFLP
CHC
164
Healthy
169
codon 10,25,-509
Pereira [19]
2008
Brazil
Mix
7
PCR-SSP
CHC
128
Healthy
94
codon 10,25
Armenda’riz-Borunda [20]
2008
Moxico
Mix
6
PCR-AS
LC
13
Healthy
30
codon 25
Fang [21]
2008
China
Asian
6
PCR-ARMS
CHC
85
Healthy
106
codon 25
Wang [22]
2005
Germany
Caucasian
7
DS
CHC
210
Healthy
50
codon 10,25
Kimura [23]
2005
Japan
Asian
6
PCR-AS
CHC
184
SR
46
-509
Zein [24]
2004
Egypt
Egyptian
8
DS
CHC
24
Healthy
47
codon 10,25
  
USA
Caucasian
8
DS
CHC
31
Healthy
36
codon 10,25
Suzuki [25]
2003
Japan
Asian
8
PCR-RFLP
CHC
206
Healthy
101
codon 10
Barrett [26]
2003
Ireland
Caucasian
5
PCR-SSP
CHC
92
SR
66
codon 10,25
Vidigal [27]
2002
Brazil
Mix
8
DS
CHC
80
Healthy
37
codon 10,25

Statistical analysis

In this paper, we quantified the relationship between the three crucial SNPs of TGF-ß1 and chronic HCV infection by pooling the ORs with its 95% CI. For the purpose of obtaining the role of these SNPs in chronic HCV infection, we used the following five gene models to extract the related statistical information: the homozygote model, the heterozygous model, the dominant comparison model, the recessive model, and the allele contrast model.
For each included study, the χ2 test is used to measure the HWE. The HWE is said to be significant if the estimator of the χ2 test is larger than 0.05. The heterogeneity of between-studies can be quantified by the Q-statistic. Additionally, the I2 statistic measures the degree of heterogeneity [28]. By the indexes of the above statistical qualification, we selected the effect model as following rules: (1) If the p-value is less than 0.10 or the value of I2 is more than 50%, then the effects are inconsistent, and the random-effects model will be selected; (2) If the p-value and the value of I2 are belonging to the exception of condition (1), then the effects are consistent, the fixed-effects model will be selected. In order to evaluate the pooling results, the Z-test is used for assessing the significance of the summary ORs.
We obtained the specific information of different ethnicities by exploring the sources of heterogeneity which is conducted by stratified analysis. Moreover, the robustness of the summary results can be assessed through sensitivity analysis. In addition, the potential publication bias of studies can be quantified by the Begg’s funnel plot and the Egger’s test [29].
These statistical analyses mentioned above were implemented on Stata 11.0 software.

Results

Studies included in the meta-analysis

The process of the included studies selection was shown in the flowchart (Fig.1). One article was regarded as two separated studies as it contained two independent case-control studies [30]. Finally, a total of 18 case-control (separated) studies were selected to conduct meta-analysis. All the selected studies have designed experiments to reveal the connections of TGF-ß1–509C/T, codon 10 T/C, and codon 25G/C polymorphisms with the susceptibility to chronic HCV infection or spontaneous clearance of HCV [6, 7, 1224, 26, 30]. These studies contain 2718 chronic HCV infection cases which correspond to 1964 controls. In the process of meta-analysis, the control subjects were composed of healthy populations [6, 7, 1216, 1822, 26, 30] and SR populations [16, 17, 23]. The gene distribution of control groups in two studies for −509C/T polymorphism was deviated from HWE [6, 12]. The stratified analysis was conducted by dividing the eligible 18 studies into the following partitions: Caucasian population (5) ˅ Asian population (5) ˅ Egyptian population (4) ˅ mixed population (4). The main detail information of each included study was summarized in Table 1. Moreover, we extracted the explicit genotype distribution of the three SNPs which were described in Additional file 1: Table S1, Additional file 2: Table S2, Additional file 3: Table S3, respectively.

Meta-analysis results

As the above mentioned, the total controls were composed of the healthy controls and SR controls. The total controls and chronic HCV infection cases were compared to obtain the generally connection of the three crucial SNPs and chronic HCV infection risk (Table 2). Different controls revealed different relationships between the three crucial SNPs and the infection/clearance of HCV. Specifically, the comparison results of the chronic HCV infected subjects with the healthy control subjects may find the connection of the three crucial SNPs and the susceptibility to chronic HCV infection (Table 3). And the comparison results of the chronic HCV infected subjects with SR control subjects may discover the connection of the three crucial SNPs and the spontaneous clearance of HCV.
Table 2
Main results of the meta-analysis of TGF-ß1 gene polymorphisms with the chronic HCV infection in total population
SNPs
 
No.of study
Gene model
OR(95%CI)
P
Heterogeneity
Publication
text
bias
P(Q-test)
I2(%)
Begg’s
Egger’s
-509
Total
7
TT vs. CC
2.081 (1.249–3.466)
0.005
0.002
73.0
0.133
0.897
   
TC vs. CC
1.880 (1.162–3.044)
0.010
0.000
79.3
0.133
0.427
 
TT + TC vs. CC
2.042 (1.240–3.361)
0.005
0.000
83.7
0.133
0.529
 
TT vs. CC + TC
1.310 (1.114–1.542)
0.001
0.208
30.3
0.260
0.918
 
T vs. C
1.503 (1.126–2.006)
0.006
0.000
81.8
0.230
0.580
Asian
2
TT vs. CC
1.242 (0.983–1.569)
0.070
0.108
61.2
1.000
  
TC vs. CC
1.074 (0.939–1.227)
0.298
0.163
48.5
1.000
 
TT + TC vs. CC
1.077 (0.976–1.190)
0.140
0.102
62.6
1.000
 
TT vs. CC + TC
1.222 (0.942–1.585)
0.131
0.234
29.4
1.000
 
T vs. C
1.375 (0.823–2.297)
0.223
0.041
76.1
1.000
Caucasian (Iran)
2
T vs. C
1.007 (0.891–1.139)
0.907
0.584
0.0
1.000
Egyptian
3
TT vs. CC
3.060 (1.529–6.122)
0.002
0.046
67.5
0.296
0.895
  
TC vs. CC
3.123 (1.339–7.284)
0.008
0.002
84.2
0.296
0.080
 
TT + TC vs. CC
3.363 (1.477–7.655)
0.004
0.001
86.1
0.296
0.168
 
TT vs. CC + TC
1.462 (1.169–1.829)
0.001
0.260
25.8
0.296
0.981
 
T vs. C
2.276 (1.295–4.001)
0.004
0.000
87.0
0.296
0.247
codon 10
Total
9
CC vs. TT
0.961 (0.802–1.151)
0.664
0.473
0.0
1.000
0.880
codon 25
  
CT vs. TT
0.961 (0.884–1.045)
0.350
0.975
0.0
0.917
0.301
 
CC + CT vs. TT
0.972 (0.911–1.037)
0.390
0.987
0.0
0.917
0.726
 
CC vs. TT + CT
1.011 (0.823–1.241)
0.917
0.179
30.0
0.917
0.676
 
C vs. T
0.980 (0.907–1.060)
0.613
0.648
0.0
1.000
0.671
Asian
2
CC vs. TT
1.074 (0.801–1.441)
0.632
0.170
46.8
1.000
  
CT vs. TT
1.929 (0.804–1.073)
0.318
0.935
0.0
1.000
 
CC + CT vs. TT
0.973 (0.873–1.085)
0.624
0.514
0.0
1.000
 
CC vs. TT + CT
1.245 (0.886–1.748)
0.206
0.107
61.5
1.000
 
C vs. T
1.029 (0.903–1.174)
0.666
0.138
54.5
1.000
Caucasian
4
CC vs. TT
0.950 (0.703–1.284)
0.737
0.350
8.6
1.000
0.976
  
CT vs. TT
1.000 (0.876–1.142)
1.000
0.891
0.0
0.734
0.818
 
CC + CT vs. TT
0.991 (0.891–1.101)
0.859
0.930
0.0
1.000
0.448
 
CC vs. TT + CT
0.934 (0.668–1.305)
0.689
0.220
32.1
1.000
0.861
 
C vs. T
0.979 (0.865–1.109)
0.740
0.605
0.0
1.000
0.844
Mix (Brazilian)
2
CC vs. TT
0.853 (0.587–1.241)
0.406
0.370
0.0
1.000
  
CT vs. TT
0.904 (0.756–1.082)
0.270
0.916
0.0
1.000
 
CC + CT vs. TT
0.924 (0.806–1.058)
0.253
0.851
0.0
1.000
 
CC vs. TT + CT
0.912 (0.588–1.417)
0.683
0.279
14.6
1.000
 
C vs. T
0.921 (0.779–1.090)
0.338
0.477
0.0
1.000
Total
11
CC vs. GG
0.744 (0.455–1.218)
0.240
0.811
0.0
0.764
0.984
  
CG vs. GG
0.940 (0.567–1.559)
0.811
0.003
63.7
0.592
0.748
 
CC + CG vs. GG
0.935 (0.570–1.534)
0.790
0.003
64.6
0.592
0.740
 
CC vs. GG + CG
0.809 (0.483–1.356)
0.421
0.931
0.0
0.548
0.879
 
C vs. G
1.000 (0.670–1.494)
1.000
0.006
59.6
0.436
0.662
Asian
2
CC vs. GG
0.917 (0.530–1.588)
0.758
0.714
0.0
1.000
  
CG vs. GG
0.896 (0.680–1.181)
0.435
0.607
0.0
1.000
 
CC + CG vs. GG
0.917 (0.732–1.148)
0.449
0.737
0.0
1.000
 
CC vs. GG + CG
0.951 (0.536–1.687)
0.863
0.712
0.0
1.000
 
C vs. G
0.923 (0.733–1.163)
0.498
0.899
0.0
1.000
Caucasian
5
CC vs. GG
0.274 (0.063–1.190)
0.084
0.513
0.0
1.000
0.880
  
CG vs. GG
1.215 (0.563–2.623)
0.620
0.042
59.7
0.806
0.333
 
CC + CG vs. GG
1.130 (0.500–2.553)
0.769
0.023
64.8
0.806
0.349
 
CC vs. GG + CG
0.339 (0.072–1.600)
0.172
0.767
0.0
1.000
0.882
 
C vs. G
1.079 (0.518–2.247)
0.839
0.031
62.4
0.462
0.339
Mix (Brazilian)
2
CC vs. GG
0.890 (0.117–6.743)
0.910
0.651
0.0
1.000
  
CG vs. GG
0.648 (0.101–4.170)
0.648
0.014
83.6
1.000
 
CC + CG vs. GG
0.691 (0.102–4.690)
0.705
0.010
84.8
1.000
 
CC vs. GG + CG
0.984 (0.126–7.706)
0.988
0.762
0.0
1.000
 
C vs. G
0.769 (0.129–4.591)
0.774
0.012
84.0
1.000
Mix
3
C vs. G
1.038 (0.272–3.965)
0.956
0.003
83.3
1.000
0.205
A random effects model was used when P-value for heterogeneity test was < 0.1; otherwise, a fixed effects model was used, and values in bold were statistically significant at P < 0.05. –, no number
CI confidence interval, OR odds ratio, SNP single-nucleotide polymorphism, P (Q-test), P-value of Q-test for heterogeneity test
Table 3
Main results of the meta-analysis of TGF-ß1 gene polymorphisms with the susceptibility to CHC compared with HL population
SNPs
 
No.of study
Gene model
OR(95%CI)
P
Heterogeneity text
Publication bias
P(Q-test)
I2(%)
Begg’s
Egger’s
-509
Total
6
TT vs. CC
1.946 (1.109–3.415)
0.020
0.002
76.2
0.221
0.949
   
TC vs. CC
1.878 (1.082–3.261)
0.025
0.000
82.9
0.221
0.453
 
TT + TC vs. CC
2.004 (1.138–3.528)
0.016
0.000
86.4
0.221
0.566
 
TT vs. CC + TC
1.282 (1.084–1.516)
0.004
0.177
36.7
0.462
0.862
 
T vs. C
1.460 (1.065–2.000)
0.019
0.000
83.9
0.452
0.644
Egyptian
3
TT vs. CC
3.060 (1.529–6.122)
0.002
0.046
67.5
0.296
0.895
  
TC vs. CC
3.123 (1.339–7.284)
0.008
0.002
84.2
0.296
0.080
 
TT + TC vs. CC
3.363 (1.477–7.655)
0.004
0.001
86.1
0.296
0.168
 
TT vs. CC + TC
1.462 (1.169–1.829)
0.001
0.260
25.8
0.296
0.981
 
T vs. C
2.276 (1.295–4.001)
0.004
0.000
87.0
0.296
0.247
Caucasian (Iran)
2
T vs. C
1.007 (0.891–1.139)
0.907
0.584
0.0
1.000
codon 10
Total
8
CC vs. TT
1.009 (0.837–1.216)
0.926
0.669
0.0
0.902
0.944
   
CT vs. TT
0.953 (0.874–1.038)
0.269
0.969
0.0
0.711
0.472
 
CC + CT vs. TT
0.974 (0.911–1.041)
0.437
0.972
0.0
1.000
0.701
 
CC vs. TT + CT
1.078 (0.870–1.336)
0.492
0.407
3.0
0.902
0.769
 
C vs. T
0.995 (0.918–1.079)
0.907
0.725
0.0
1.000
0.811
Asian
2
CC vs. TT
1.074 (0.801–1.441)
0.632
0.170
46.8
1.000
  
CT vs. TT
1.929 (0.804–1.073)
0.318
0.935
0.0
1.000
 
CC + CT vs. TT
0.973 (0.873–1.085)
0.624
0.514
0.0
1.000
 
CC vs. TT + CT
1.245 (0.886–1.748)
0.206
0.107
61.5
1.000
 
C vs. T
1.029 (0.903–1.174)
0.666
0.138
54.5
1.000
Caucasian
3
CC vs. TT
1.098 (0.786–1.534)
0.585
0.882
0.0
0.296
0.296
  
CT vs. TT
0.987 (0.855–1.139)
0.854
0.784
0.0
1.000
0.682
 
CC + CT vs. TT
1.000 (0.892–1.122)
0.995
0.859
0.0
1.000
0.661
 
CC vs. TT + CT
1.114 (0.764–1.626)
0.575
0.779
0.0
0.296
0.103
 
C vs. T
1.022 (0.890–1.173)
0.763
0.956
0.0
1.000
0.942
Mix (Brazilian)
2
CC vs. TT
0.853 (0.587–1.241)
0.406
0.370
0.0
1.000
  
CT vs. TT
0.904 (0.756–1.082)
0.270
0.916
0.0
1.000
 
CC + CT vs. TT
0.924 (0.806–1.058)
0.253
0.851
0.0
1.000
 
CC vs. TT + CT
0.912 (0.588–1.417)
0.683
0.279
14.6
1.000
 
C vs. T
0.921 (0.779–1.090)
0.338
0.477
0.0
1.000
codon 25
Total
9
CC vs. GG
0.740 (0.450–1.219)
0.237
0.702
0.0
0.452
0.908
   
CG vs. GG
0.832 (0.501–1.383)
0.479
0.012
59.2
0.754
0.693
 
CC + CG vs. GG
0.835 (0.505–1.382)
0.484
0.008
61.3
0.754
0.713
 
CC vs. GG + CG
0.814 (0.482–1.373)
0.440
0.869
0.0
0.707
0.872
 
C vs. G
0.933 (0.612–1.422)
0.747
0.010
58.7
0.371
0.634
Asian
2
CC vs. GG
0.917 (0.530–1.588)
0.758
0.714
0.0
1.000
  
CG vs. GG
0.896 (0.680–1.181)
0.435
0.607
0.0
1.000
 
CC + CG vs. GG
0.917 (0.732–1.148)
0.449
0.737
0.0
1.000
 
CC vs. GG + CG
0.951 (0.536–1.687)
0.863
0.712
0.0
1.000
 
C vs. G
0.923 (0.733–1.163)
0.498
0.899
0.0
1.000
Caucasian
4
CC vs. GG
0.208 (0.037–1.172)
0.075
0.357
0.0
1.000
  
CG vs. GG
0.913 (0.599–1.391)
0.672
0.111
50.2
0.734
0.500
 
CC + CG vs. GG
0.878 (0.317–2.428)
0.802
0.029
66.9
0.734
0.482
 
CC vs. GG + CG
0.283 (0.047–1.722)
0.171
0.545
0.0
1.000
 
C vs. G
0.869 (0.329–2.300)
0.778
0.028
66.9
0.734
0.518
Mix (Brazilian)
2
CC vs. GG
0.890 (0.117–6.743)
0.910
0.651
0.0
1.000
  
CG vs. GG
0.648 (0.101–4.170)
0.648
0.014
83.6
1.000
 
CC + CG vs. GG
0.691 (0.102–4.690)
0.705
0.010
84.8
1.000
 
CC vs. GG + CG
0.984 (0.126–7.706)
0.988
0.762
0.0
1.000
 
C vs. G
0.769 (0.129–4.591)
0.774
0.012
84.0
1.000
A random effects model was used when P-value for heterogeneity test was < 0.1; otherwise, a fixed effects model was used, and values in bold were statistically significant at P < 0.05
CHC chronic hepatitis C; CI confidence interval, HL healthy, OR odds ratio, SNP single-nucleotide polymorphism; P (Q-test) P-value of Q-test for heterogeneity test

TGF-ß1–509C/T polymorphism (rs1800469) and chronic HCV infection

Seven studies investigated the connection between the TGF-ß1–509C/T polymorphism and the chronic HCV infection. Two of them didn’t satisfy the HWE rule by χ2 test [6,12], and another article just reported the allele distribution of T and C [17]. By the adaptive selection effect models, the effects of pooling included studies revealed that −509TT genotype and T allele may significantly increase the risk of chronic HCV infection in all genetic models (Fig. 2 and Table 2). In addition, the results of subgroup analyses by ethnicity presented that the polymorphism of -509C/T may significantly increase the risk of chronic HCV infection for Egyptians (Fig. 3 and Table 2).
The results of meta-analysis which contrasted the chronic HCV infected patients and healthy controls revealed that -509TT genotype and T allele promoted a higher risk of susceptibility to the chronic HCV infection in all gene models (Fig. 4 and Table 3). For the ethnicity subgroup analyses, more significant connection of -509TT genotype and T allele and chronic HCV infection was found in the Egyptian population (Fig. 3 and Table 3).
Since only one included study reported the comparison of chronic HCV infected cases and SR controls, we couldn’t conduct the pooling strategy (meta-analysis) to assess the association between the polymorphism of -509C/T and the spontaneous clearance of HCV [14].
The related summary effects (ORs) rarely changed after we excluded the studies that didn’t follow the HWE (Figs. 5, 6 and 7 and Table 4).
Table 4
Main results of the meta-analysis of TGF-ß1 gene polymorphisms in populations following HWE
SNPs
 
No.of study
Gene model
OR(95%CI)
P
Heterogeneity text
Publication bias
P(Q-test)
I2(%)
Begg’s
Egger’s
-509
Total (HWE)
5
TT vs. CC
1.507 (1.262–1.799)
0.000
0.115
49.4
1.000
0.400
   
TC vs. CC
1.240 (1.117–1.377)
0.000
0.394
0.0
1.000
0.304
  
TT + TC vs. CC
1.200 (1.113–1.295)
0.000
0.170
40.2
1.000
0.353
  
TT vs. CC + TC
1.141 (0.935–0.393)
0.193
0.504
0.0
1.000
0.563
  
T vs. C
1.374 (1.074–1.758)
0.011
0.022
65.0
0.806
0.403
Egyptian (HWE)
2
TT vs. CC
1.567 (1.284–1.912)
0.000
0.244
26.3
1.000
(CHC-healthy)
 
TC vs. CC
1.272 (1.128–1.434)
0.000
0.437
0.0
1.000
  
TT + TC vs. CC
1.225 (1.124–1.336)
0.000
0.302
6.3
1.000
  
TT vs. CC + TC
1.407 (1.120–1.768)
0.003
0.372
0.0
1.000
  
T vs. C
1.270 (1.153–1.399)
0.000
0.223
32.7
1.000
Total (HWE)
4
TT vs. CC
1.462 (1.215–1.760)
0.000
0.075
61.4
1.000
0.411
(CHC-healthy)
 
TC vs. CC
1.230 (1.101–1.373)
0.000
0.246
28.7
1.000
0.355
  
TT + TC vs. CC
1.189 (1.098–1.288)
0.000
0.102
56.2
1.000
0.384
  
TT vs. CC + TC
1.323 (1.069–1.636)
0.010
0.212
35.5
1.000
0.427
  
T vs. C
1.300 (0.991–1.707)
0.058
0.020
69.3
0.308
0.228
codon 25
Total (HWE)
10
CC vs. GG
0.701 (0.417–1.180)
0.182
0.735
0.0
1.000
0.987
   
CG vs. GG
0.974 (0.550–1.724)
0.927
0.002
67.5
0.602
0.775
  
CC + CG vs. GG
0.956 (0.543–1.683)
0.875
0.001
68.5
0.754
0.769
  
CC vs. GG + CG
0.766 (0.443–1.325)
0.341
0.896
0.0
1.000
0.924
  
C vs. G
0.973 (0.626–1.512)
0.902
0.007
60.6
0.371
0.708
Total (HWE)
8
CC vs. GG
0.696 (0.411–1.179)
0.178
0.596
0.0
0.806
0.913
(CHC-healthy)
 
CG vs. GG
0.853 (0.474–1.533)
0.594
0.007
64.2
0.711
0.722
  
CC + CG vs. GG
0.843 (0.468–1.518)
0.569
0.004
66.2
0.902
0.736
  
CC vs. GG + CG
0.769 (0.441–1.342)
0.356
0.803
0.0
0.806
0.886
  
C vs. G
0.864 (0.516–1.444)
0.576
0.008
63.4
0.711
0.723
A random effects model was used when P-value for heterogeneity test was < 0.1; otherwise, a fixed effects model was used, and values in bold were statistically significant at P < 0.05. –, no number
CHC chronic hepatitis C, CI confidence interval, HWE Hardy–Weinberg equilibrium, OR odds ratio, SNP single-nucleotide polymorphism, P (Q-test), P-value of Q-test for heterogeneity test

TGF-ß1 codon 10 T/C polymorphism (rs1982073) and chronic HCV infection

Nine studies investigated the connection between the polymorphism of codon 10 T/C and the chronic HCV infection. The summary results revealed no strong connections between the codon 10 T/C polymorphism and the risk of chronic HCV infection in total or subgroup analyses (Tables 2 and 3). Only one study compared the patients with the SR controls, therefore, we were unable to evaluate the association of this SNP with the spontaneous clearance of HCV [23].

TGF-ß1 codon 25G/C polymorphism (rs1800471) and chronic HCV infection

Eleven studies explored the role of the codon 25G/C polymorphism on the chronic HCV infection. One of them just reported the allele distribution of C and G [17]. Overall, the pooling estimates showed no significant association between the codon 25G/C polymorphism and chronic HCV infection in all comparison models of total or subgroup analyses (Tables 2 and 3).
We were able to compare the chronic HCV infected cases with SR controls in the contrast of C vs. G in two studies [17, 23], but the pooling estimates showed the codon 25G/C polymorphism was not associated with the spontaneous clearance of HCV (C vs. G: OR = 1.286, 95% CI = 0.768–2.153, P = 0.338).

Sensitivity analysis

To test the stability of the summary effects model, we conducted the sensitive analysis by successively excluding single study. The summary effects were said stable if the pooling results rarely changed as the included studies successively were excluded. Take the analysis of -509C/T polymorphism in total control group as an example, when we successively excluded the studies with different data properties: Ma’s study which didn’t follow HWE; Mohy’s study whose sample size was the smallest one; and Pasha’s study whose sample size was the biggest one. The corresponding summary ORs were little altered (OR = 2.401, 95% CI = 1.350–4.270, P = 0.003; OR = 1.591, 95% CI = 1.106–2.290, P = 0.010; OR = 2.209, 95% CI = 1.130–4.320, P = 0.000, successively) (Additional file 5: Figure S1).

Publication bias

The potential publication bias of studies for our meta-analysis conducted by the Begg’s funnel plot and the Egger’s test. The result indicated that publication bias of studies played a rare influence on our meta-analysis.

Discussion

Millions of people are infected with HCV which can be considered as one of the most frequent infectious diseases. It is still not clear about the reason that caused the differences in the outcome of HCV-infected patients and how to effectually clear the HCV from human body. Lots of researchers worked on finding the risk factors which may explain the curative mechanism of HCV infection. Although multiple factors have been reported, the genetic factors are thought as relative radical solutions for the curative mechanism of HCV infection. Recently, several papers presented that the polymorphisms of TGF-β1 may be responsible for HCV infection by affecting the expression and secretion of some cytokines. Since experiment data of individual study always shows imbalance of the structural which specifically performed as the difference in data size, ethnicities, regions and so on, the studies focusing on same subjects obtained controversial conclusions. These controversial conclusions were detrimental to clinical practice.
Through the comprehensive meta-analysis of the three SNPs locus (−509C/T, codon 10 T/C, and codon 25G/C) in TGF-ß1 gene connecting with chronic HCV infection, we observed that -509C/T polymorphism might be a risk locus for chronic HCV infection, and the results of meta-analysis showed that this gene correlation were especially salient in Egyptians. However, the polymorphisms of codon 10 T/C or codon 25G/C exhibited no association with chronic HCV infection in total or subgroup analyses.
To further discriminate the effect of infection or clearance, we compared the chronic HCV infected patients with healthy controls or SR controls, respectively. Specifically, the summary results of our meta-analysis revealed that subjects with the genotype of -509TT and T allele have a about 2 and 3 fold higher stake of the susceptibility to chronic HCV infection in total and Egyptian populations, respectively. Moreover, the related summary effects (ORs) rarely changed after we excluded the studies that didn’t follow the HWE. A series of statistical tests which included the HWE test, sensitivity analysis and publication bias test guaranteed the related pooling ORs were stable, definite and statistically significant.
Several studies reported the polymorphism of codon 10 T/C was located at position + 29, relative the translational start site of TGF-ß1 gene. The transition of T to C of the codon 10 may impact the export productivity of the newly synthesized protein [10, 11]. Wang et al suggested the codon 10C allele was likely to develop more severe fibrosis during chronic HCV infection [19]. And Vidigal et al reported the codon 10CC genotype was associated with the resistance to combined antiviral therapy in HCV infection [26]. However, in most other studies, the polymorphism of codon 10 T/C was not related to the chronic HCV infection [15, 16, 2123, 30]. And our meta-analysis summary results of this SNP were consistent with the majority opinion. The deterministic correlation of codon 10 T/C polymorphism and chronic HCV infection needs more case-controls studies to confirm.
Another crucial SNP locus is codon 25G/C which may impact the production of TGF-β1. The transition of G to C may be correlated with the reduced level of TGF-β1 in vitro [27]. Pereira et al reported that the CHC patients have the higher frequency of codon 25G allele than healthy subjects [21]. Theoretically, it is plausible that subjects with the high TGF-β1 producer phenotype which is associated with the codon 25G allele present over suppression in the human immune response. This mechanism may result in the correlation of the polymorphism of codon 25G/C and chronic HCV infection. However, one previous meta-analysis demonstrated that the polymorphism of TGF-β1 codon 25G/C wasn’t correlated with the chronic HCV infection [31]. In our proposed meta-analysis, the summary results were obtained by pooling the data from the latest and most complete studies and conducting the total analysis, subgroup analyses and the different comparison of controls analyses. Eventually, we didn’t find the connection between the polymorphism of TGF-β1 codon 25G/C and the chronic HCV infection. Several factors may contribute to the discrepancy. First, the small size samples of included studies were insufficient to mining the deep connections of the certain genotype and certain clinical disease. Second, some impacted heterogeneity still existed, although we conducted subgroup analyses by the ethnicity and control groups as well as dropped the studies which did not satisfy the HWE rule to explore the sources of heterogeneity. Moreover, other factors such as other polymorphisms or viral factors of the chronic HCV infection may be involved. Notably, the codon 25 polymorphism has been revealed to be connected with the stage/degree of liver fibrosis in Caucasian HCV infected patients [32, 33]. A large-scale study is thereby required to confirm the genetic contribution to HCV infection or live fibrosis.
Due to the unique SR controls of related studies, we weren’t able to use meta-analysis to access the connection of the -509C/T or codon 10 T/C polymorphisms with the clearance of HCV. Moreover, the proposed meta-analysis results of two studies in the gene model of C vs. G showed that no significant association was found between the polymorphism of -25G/C and the spontaneous clearance of HCV. So deep researchs are warranted to accurately clarify the correlation of these SNPs and the spontaneous clearance of HCV.
Previous study reported high differences of these allelic frequencies from different ancestries [22]. Therefore, we conducted subgroup analyses by the ethnicity. The populations from Iran, Germany, American-Caucasian, and Ireland were classified as the Caucasians; the populations from Japan, Pakistan, and China were classified as the Asians; and the populations from Brazil, Morocco, and Mexico were classified as the mixed races populations. For the race of Egyptian, we searched for the relevant articles and consulted the geographers, but the results were inconsistent. In order to reduce the substantial genetic heterogeneity, we categorized the Egyptian as a separate subgroup.
For the purpose of accurately interpreting the results of this meta-analysis, several potential limitations should be declared. First, although we collected all published studies, the number of included study cases specific to each site was still limited, especially for the researches on the connection of spontaneous clearance of HCV. Randomized controlled clinical studies with larger sample sizes and multi-ethnic populations are required. Second, HCV infection and disease progression are influenced by multiple factors, and the potential gene-gene or gene-environment interactions should be conducted relative research. Finally, because some researches did not provide information such as gender, age and environmental factors, it is hard for us to study the effects of these factors on the connection of the polymorphisms of TGF-ß1 gene with chronic HCV infection by a subgroup analysis.

Conclusion

Taken together, our results suggested that the TGF-ß1–509 TT genotype and T allele were connected with a higher incidence of chronic HCV infection, and this connection was especially significant in Egyptians. In future studies, more researches with large scale samples and detail information will be required to enhance or correct the summary conclusions of the meta-analysis.

Acknowledgments

The researchers would like to thank everyone who helped with this study.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–15.CrossRef Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–15.CrossRef
2.
Zurück zum Zitat Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–29.CrossRef Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–29.CrossRef
3.
Zurück zum Zitat Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama. 2000;284:450–6.CrossRef Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama. 2000;284:450–6.CrossRef
4.
Zurück zum Zitat Bengsch B, Thimme R, Blum HE. Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses. 2009;1:104–25.CrossRef Bengsch B, Thimme R, Blum HE. Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses. 2009;1:104–25.CrossRef
5.
Zurück zum Zitat Sun XR, Wu J, Shi KQ, Tang KF. Relationship between IL-10 gene -1082A/G and -592C/a polymorphisms and the risk of hepatitis C infection: a meta-analysis. J Viral Hepat. 2013;20:602–11.CrossRef Sun XR, Wu J, Shi KQ, Tang KF. Relationship between IL-10 gene -1082A/G and -592C/a polymorphisms and the risk of hepatitis C infection: a meta-analysis. J Viral Hepat. 2013;20:602–11.CrossRef
6.
Zurück zum Zitat Mohy A, Fouad A. Role of transforming growth factor-beta1 in serum and - 509 C>T promoter gene polymorphism in development of liver cirrhosis in Egyptian patients. Meta Gene. 2014;2:631–7.CrossRef Mohy A, Fouad A. Role of transforming growth factor-beta1 in serum and - 509 C>T promoter gene polymorphism in development of liver cirrhosis in Egyptian patients. Meta Gene. 2014;2:631–7.CrossRef
7.
Zurück zum Zitat Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-beta1 and tumor necrosis factor-alpha genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60:271–6.CrossRef Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-beta1 and tumor necrosis factor-alpha genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60:271–6.CrossRef
8.
Zurück zum Zitat Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ. 2003;10(Suppl 1):S59–67.CrossRef Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ. 2003;10(Suppl 1):S59–67.CrossRef
9.
Zurück zum Zitat Kondo Y, Ueno Y, Shimosegawa T. Dysfunction of immune systems and host genetic factors in hepatitis C virus infection with persistent Normal ALT. Hepat Res Treat. 2011;2011:713216.PubMedPubMedCentral Kondo Y, Ueno Y, Shimosegawa T. Dysfunction of immune systems and host genetic factors in hepatitis C virus infection with persistent Normal ALT. Hepat Res Treat. 2011;2011:713216.PubMedPubMedCentral
10.
Zurück zum Zitat Fujii D, Brissenden JE, Derynck R, Francke U. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet. 1986;12:281–8.CrossRef Fujii D, Brissenden JE, Derynck R, Francke U. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet. 1986;12:281–8.CrossRef
11.
Zurück zum Zitat Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8:93–7.CrossRef Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8:93–7.CrossRef
12.
Zurück zum Zitat Ma J, Liu YC, Fang Y, Cao Y, Liu ZL. TGF-beta1 polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. Genet Mol Res. 2015;14:4461–8.CrossRef Ma J, Liu YC, Fang Y, Cao Y, Liu ZL. TGF-beta1 polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. Genet Mol Res. 2015;14:4461–8.CrossRef
13.
Zurück zum Zitat Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine. 2013;61:478–84.CrossRef Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine. 2013;61:478–84.CrossRef
14.
Zurück zum Zitat Kimura T, Saito T, Yoshimura M, Yixuan S, Baba M, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis. 2006;193:1371–4.CrossRef Kimura T, Saito T, Yoshimura M, Yixuan S, Baba M, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis. 2006;193:1371–4.CrossRef
15.
Zurück zum Zitat Romani S, Azimzadeh P, Mohebbi SR, Kazemian S, Almasi S, et al. Investigation of transforming growth factor-beta1 gene polymorphisms among Iranian patients with chronic hepatitis C. Hepat Mon. 2011;11:901–6.CrossRef Romani S, Azimzadeh P, Mohebbi SR, Kazemian S, Almasi S, et al. Investigation of transforming growth factor-beta1 gene polymorphisms among Iranian patients with chronic hepatitis C. Hepat Mon. 2011;11:901–6.CrossRef
16.
Zurück zum Zitat Imran M, Manzoor S, Parvaiz F. Predictive potential of IL-18 -607 and osteopontin −442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol. 2014;27:404–11.CrossRef Imran M, Manzoor S, Parvaiz F. Predictive potential of IL-18 -607 and osteopontin −442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol. 2014;27:404–11.CrossRef
17.
Zurück zum Zitat Rebbani K, Ezzikouri S, Marchio A, Ababou M, Kitab B, et al. Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population. Infect Genet Evol. 2014;26:1–7.CrossRef Rebbani K, Ezzikouri S, Marchio A, Ababou M, Kitab B, et al. Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population. Infect Genet Evol. 2014;26:1–7.CrossRef
18.
Zurück zum Zitat Armendariz-Borunda J, Rincon AR, Munoz-Valle JF, Bueno-Topete M, Oregon-Romero E, et al. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential Correlation with pirfenidone treatment. J Investig Med. 2008;56:944–53.CrossRef Armendariz-Borunda J, Rincon AR, Munoz-Valle JF, Bueno-Topete M, Oregon-Romero E, et al. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential Correlation with pirfenidone treatment. J Investig Med. 2008;56:944–53.CrossRef
19.
Zurück zum Zitat Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11:1929–36.CrossRef Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, et al. Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11:1929–36.CrossRef
20.
Zurück zum Zitat Fang J, Liu ZW, Han QY. Polymorphism of codon25 in signal peptide region of transforming growth factor beta 1 and its association with chronic hepatitis C virus infection. Zhonghua Gan Zang Bing Za Zhi. 2008;16:586–9.PubMed Fang J, Liu ZW, Han QY. Polymorphism of codon25 in signal peptide region of transforming growth factor beta 1 and its association with chronic hepatitis C virus infection. Zhonghua Gan Zang Bing Za Zhi. 2008;16:586–9.PubMed
21.
Zurück zum Zitat Pereira FA, Pinheiro da Silva NN, Rodart IF, Carmo TM, Lemaire DC, et al. Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol. 2008;80:58–64.CrossRef Pereira FA, Pinheiro da Silva NN, Rodart IF, Carmo TM, Lemaire DC, et al. Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol. 2008;80:58–64.CrossRef
22.
Zurück zum Zitat Suzuki S, Tanaka Y, Orito E, Sugauchi F, Hasegawa I, et al. Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003;18:1139–43.CrossRef Suzuki S, Tanaka Y, Orito E, Sugauchi F, Hasegawa I, et al. Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003;18:1139–43.CrossRef
23.
Zurück zum Zitat Barrett S, Collins M, Kenny C, Ryan E, Keane CO, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol. 2003;71:212–8.CrossRef Barrett S, Collins M, Kenny C, Ryan E, Keane CO, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol. 2003;71:212–8.CrossRef
24.
Zurück zum Zitat Larijani MS, Rad LN, Nikbin M, Bahiraei N, Javadi F, et al. Impact of TGF-beta1 gene polymorphism (rs1800469) on treatment response to Pegylated interferon/ribavirin in Iranian patients with hepatitis C. Clin Lab. 2016;62:609–14.PubMed Larijani MS, Rad LN, Nikbin M, Bahiraei N, Javadi F, et al. Impact of TGF-beta1 gene polymorphism (rs1800469) on treatment response to Pegylated interferon/ribavirin in Iranian patients with hepatitis C. Clin Lab. 2016;62:609–14.PubMed
25.
Zurück zum Zitat Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100:4120–5.CrossRef Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100:4120–5.CrossRef
26.
Zurück zum Zitat Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol. 2002;36:271–7.CrossRef Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol. 2002;36:271–7.CrossRef
27.
Zurück zum Zitat Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014–20.CrossRef Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014–20.CrossRef
28.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.CrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.CrossRef
29.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–34.CrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–34.CrossRef
30.
Zurück zum Zitat Zein NN, Germer JJ, El-Zayadi AR, Vidigal PG. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg. 2004;70:434–7.CrossRef Zein NN, Germer JJ, El-Zayadi AR, Vidigal PG. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg. 2004;70:434–7.CrossRef
31.
Zurück zum Zitat Hu GR, Zheng BX, Liu ZF. Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: a meta-analysis. Biomed Rep. 2014;2:239–44.CrossRef Hu GR, Zheng BX, Liu ZF. Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: a meta-analysis. Biomed Rep. 2014;2:239–44.CrossRef
32.
Zurück zum Zitat Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828–33.CrossRef Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828–33.CrossRef
33.
Zurück zum Zitat Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83–94.CrossRef Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83–94.CrossRef
Metadaten
Titel
Association of TGF-ß1 polymorphisms and chronic hepatitis C infection: a Meta-analysis
verfasst von
Pengfei Guo
Shuangyin Liu
Xiangru Sun
Longqin Xu
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2019
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4390-8

Weitere Artikel der Ausgabe 1/2019

BMC Infectious Diseases 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.